-+ 0.00%
-+ 0.00%
-+ 0.00%

Barclays Maintains Overweight on Teva Pharmaceutical Indus, Raises Price Target to $50

Benzinga·11/19/2026 15:26:03
Diffusion vocale
Barclays analyst Glen Santangelo maintains Teva Pharmaceutical Indus (NYSE:TEVA) with a Overweight and raises the price target from $47 to $50.